Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Duchenne muscular dystrophy (DMD)
Biotech
Regenxbio gene therapy passes interim test as pivotal data loom
Regenxbio has guided its DMD gene therapy candidate through another test, reporting a clean safety profile and functional improvements.
Nick Paul Taylor
Mar 12, 2026 5:49am
FDA reconsidering Capricor’s snubbed DMD cell therapy
Mar 10, 2026 11:14am
‘Bureaucratic idiocy’: GOP senator to investigate FDA rejections
Mar 10, 2026 11:10am
Fierce Pharma
Sarepta CEO to retire, citing 'shocking and ironic twist of fate'
Feb 26, 2026 11:30am
Dyne readies FDA push after DMD exon 51 med excels in trial
Dec 8, 2025 10:50am
Capricor sets up 2nd DMD approval attempt with ph. 3 win
Dec 3, 2025 11:11am
